Compare Royal Bank of Canada (RY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs TG Therapeutics Inc — how do they compare? Royal Bank of Canada trades at $214.99 (market cap $292.32B), while TG Therapeutics Inc trades at $50 (market cap $7.64B). The key difference: Royal Bank of Canada is far larger — about 38.3× TG Therapeutics Inc's market cap, and Royal Bank of Canada pays a 2.37% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RY | TGTX | |
|---|---|---|
Market Cap | $292.32B | $7.64B |
Sector | Financials | Health |
52-Week High | $217.87 | $59.06 |
52-Week Low | $135.91 | $26.94 |
Dividend Yield | 2.37% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $213.35, up 1.21% today, with a bullish technical signal and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $2.84 versus $2.81 expected, and a 30.6% net income margin in 2025 highlight robust profitability. The stock is supported by a dividend of $1.76 payable in August 2026 and positive analyst coverage, though insider selling and high valuation metrics warrant attention.
RY's outlook remains positive with projected 2026 revenue of $69.5B and net income of $22.1B, but risks include elevated P/E of 19.07, significant debt levels, and potential macroeconomic pressures on the banking sector. The stock offers steady growth and income, yet investors should weigh valuation concerns against strong operational trends.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
